Jagsonpal Pharmaceuticals Seals Deal to Acquire Yash Pharma’s India and Bhutan Businesses
Jagsonpal acquires Yash Pharma's India & Bhutan businesses, expanding into dermatology and paediatrics.
Breaking News
Jun 18, 2024
Mrudula Kulkarni

Jagsonpal Pharmaceuticals announced the acquisition of the India and Bhutan businesses of Yash Pharma. This particular transaction, facilitated by boutique investment banking firm “Growthally Advisors”, is expected to not only expand the therapeutic reach of Jagsonpal but will also have a strong bearing on improving its market ranking.
This merger is particularly notable because it combines two companies with different but complementary expertise. Jagsonpal, renowned for its 60-year history and expertise in gynaecology and orthopaedics, will now integrate Yash Pharma's extensive portfolio of 33 well-established brands in dermatology and paediatrics, further strengthening their combined offerings. This strategic decision not only expands Jagsonpal's range of products but also enables them to enter a new market segment valued at ₹20,000 crore (Source: IQVIA), which offers substantial growth prospects.
A spokesperson for Jagsonal stated that “This acquisition is the perfect recipe for Jagsonpal. Yash Pharma's strengths in dermatology and paediatrics can now be leveraged to align with our long-term growth objectives. Now, with our portfolio getting extended with this access to new customer segments, the company is poised to significantly strengthen our market position.”
Bhupinder Garg, who is the Managing Director (MD), Growthally Advisors said, “We are proud to have been facilitators of this mutually rewarding partnership. We believe that this transaction is a perfect example of how strategic acquisitions can ensure benefits for all stakeholders." He further added, "The Indian pharmaceutical sector in particular, will be growing at a significant rate. Strategically planned collaborations and acquisitions will prove to be major driving forces towards unlocking the huge potential this industry has!"
This particular acquisition places Jagsonpal in a strong position to continue its growth and innovation journey. They are expected to leverage this expanded portfolio to further strengthen their market presence. Operational synergies with Yash Pharma are also expected to drive profitability for both players, giving them the power to deliver greater value to its customers and stakeholders.